Patents (1436 Stem Cell Patents)

Class: Use (276)

Order by:
1 2 3 4 5 | > | >>

Treatment of muscular dystrophy with cord blood cells

Patent Number: 7,452,529

Cord blood stem cells are currently approved only for hematopoietic reconstitution, however numerous experimental uses are being reported.  Given that cord blood stem cells have been reported to possess pluripotent characteristics, a wide variety of new indications are being developed.  For example...

Inventors: Brown, Jr.; Robert H. (Needham, MA), Finklestein; Seth P. (Needham, MA), Kraus; Morey (Jefferson, MA)
Assignee: Viacell, Inc. (Worchester, MA); The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Wednesday July 23rd, 2008

Telomerase promoters sequences for screening telomerase modulators

Patent Number: 7,378,244

Division of most mammalian cells is accompanied by reduction in the length of telomeres, which is responsible in part for cellular senescence and death. Some cells, particularly stem cells and cancer cells, express the enzyme telomerase and are not restricted by the "Hayflick Limit". Some data exists to support the concept...

Inventors: Morin; Gregg B. (Vancouver, CA), Lichtsteiner; Serge (Encinitas, CA), Vasserot; Alain (Carlsbad, CA), Adams; Robert (Redwood City, CA), Andrews; William H. (Reno, NV)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Friday May 30th, 2008 1 Comment

Cosmetic compositions

Patent Number: 7,405,195

The current patent covers a cosmetic generated using a variant of stromal derived factor (SDF-1) which the inventors termed stem cell active factor (SCAF).  The natural function of SDF-1 is to call in stem cells to injured tissue, for example, after a heart attack there is a surge of SDF-1 which is involved in mediating mobilization of stem cells from the bone...

Assignee: Natural Beauty Bio-Technology Limited (Taipei, TW)

Implantable cell/tissue-based biosensing device

Patent Number: 7,519,409

The current patent covers a device useful for detecting chemicals in a patient, with the device being implantable.  Practically the device claimed is used for implantation into the heart and provides information via electrical signals as to the chemical environment based on changes to the "biosensing" cells. 

In its first claim, the patent covers "a biosensor...

Inventors: Yang; Zhongping (Woodbury, MN), Reinke; James D. (Maple Grove, MN)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Date of First Priority Issue: Thursday December 29th, 2005

Stromal antigen-presenting cells and use thereof

Patent Number: 7,553,661

Mesenchymal stem cells are known to possess a variety of immune modulatory activities such as suppression of allogeneic responses, as well as induction of T regulatory cells.  Mechanisms include expression of IDO and HLA-G.  Mesenchymal stem cells have been demonstrated effective in patients with...

Inventors: Galipeau; Jacques (Town of Mount-Royal, CA), Stagg; John (Montreal, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Tuesday May 31st, 2005

Methods for assisting recovery of damaged brain and spinal cord using arrays of X-ray microplanar beams

Patent Number: 7,158,607

One of the problems with cell therapy after injury is the possibility of accelerating scar tissue formation. The current patent teaches the use of X-rays, administered by parallel micro-beams at doseages that are sufficient to remove inhibitors of regeneration. The patent also discloses the use of exogenous stem cells in combination with the X-rays in order to accelerate healing.

Inventors: Dilmanian; F. Avraham (Yaphank, NY), McDonald, III; John W. (Baltimore, MD)
Assignee: Brookhaven Science Associates, LLC (Upton, NY)
Date of First Priority Issue: Thursday February 10th, 2005

Methods for assisting recovery of damaged brain and spinal cord using arrays of X-Ray microplanar beams

Patent Number: 7,305,064

It has always been the belief of that the future of stem cell therapeutics is not only in the development and use of stem cell types, but the integration of stem cells with other modalities to attain synergy. For example, while FDA/EMEA development of cellular product candidates takes years and hundreds of millions of dollars, the same, or very...

Inventors: Dilmanian; F. Avraham (Yaphank, NY), McDonald, III; John W. (Baltimore, MD)
Assignee: Brookhaven Science Associates, LLC (Upton, NY)
Date of First Priority Issue: Thursday February 10th, 2005

Compositions and methods for detecting and treating motor neuron disorders

Patent Number: 7,384,748

The issued claim in the current patent covers a method of diagnosing a motor neuron disease based on sequences associated with mutations in the neuropathy target esterase (NTE) gene. If one reads the specification, descriptions of treatments based on inhibiting expression of the mutated NTE gene using techniques such as siRNA are disclosed. Genetic complementation using stem cells are also...

Inventors: Fink; John K. (Ann Arbor, MI), Rainer; Shirley (Sylvania, OH)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday December 13th, 2004

Compositions, systems and methods for treatment of defects in blood vessels

Patent Number: 7,201,918

Vascular aneurysms are thinning of blood vessel walls, which is usually associated with vessel trauma, non-specific degeneration, atherosclerosis, or infection. The term "aneurysm" comes from the Latin "aneurysma" which means "dilation". Aneurysms are hazardous because of the potential to burst. They are usually prevelant in the aorta or cerebral arteries. The current patent provides...

Inventors: Cruise; Gregory M. (Rancho Santa Margarita, CA)
Assignee: Microvention, Inc. (Aliso Viejo, CA)
Date of First Priority Issue: Tuesday November 16th, 2004

Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site

Patent Number: 7,524,490


Many diseases are associated with either too much apoptosis (eg ALS, Parkinson's, Liver failure, etc) or too little apoptosis (cancer).  The current patent covers a method to suppress apoptosis in mammalian cells.

The method consists of transfecting an isolated population bone marrow derived stromal cells (either autologous or allogeneic) with a nucleic acid encoding the...

Inventors: Geng; Yong-Jian (Pearland, TX)
Assignee: Board of Regents The University of Texas (Austin, TX)
Date of First Priority Issue: Wednesday November 10th, 2004

Order by:
1 2 3 4 5 | > | >>

Home | News | Patents | Products | Jobs | Links | Search | Journal | RSS

About | Advisory Board | Newsletter | Advertise | Contact | Sitemap | Privacy Policy | Terms of Use

Copyright © 2006 - 2021 - All rights reserved. - Toronto Web Design V2.10